FDA Approves Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma By Ogkologos - November 6, 2025 70 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the DREAMM-7 study Source RELATED ARTICLESMORE FROM AUTHOR Ahead of ESMO Immuno-Oncology Congress 2025: topics at a glance Aiming to Prevent Cancer Cases, ESMO Calls Against Misleading Alcohol-Labelling Following European Parliament Vote on the EU Wine Package ESMO Call for Cancer Care Safeguards Reflected in the EU’s Health Crisis Preparedness Plan MOST POPULAR How to Talk With Your Children About Your Metastatic Cancer Prognosis September 2, 2021 Occurrence of Interstitial Lung Disease Related to Trastuzumab Deruxtecan in Patients... May 8, 2021 Durable Antitumour Activity of Pembrolizumab Plus Lenvatinib in Patients with Previously... July 25, 2023 FDA Grants Accelerated Approval to Infigratinib for Metastatic Cholangiocarcinoma June 2, 2021 Load more HOT NEWS Altering Chemotherapy Improves Outcomes in Early-Stage Pancreatic Cancer To Improve Immunotherapy, Researchers Look at Limiting Cancer’s Access to Sugar... More Than 25 Additional Years Needed to Slow an Increasing Incidence... Survival According Circulating Tumour DNA Status in the Study of Adjuvant...
